Skip to content

Study · Animal study (in vivo) · guinea pig · 2002

2 results

Co-treatment with melanotan-II, a potent melanocortin, does not protect against cisplatin ototoxicity.

Wolters FL, de Vocht TF, Klis SF, Hamers FP, Smoorenburg GF

Hearing research1 Oct 2002Cited by 1 (Europe PMC)

PMID12361873 (opens in a new tab)DOI10.1016/s0378-5955(02)00551-8 (opens in a new tab)PepBankPUB-12361873
Publisher pagePubMedAsk about this study
Jump to 2 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study2

2 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Efficacy outcome

    In guinea pigs given cisplatin, co-treatment with MT-II did not change the number of days to a 40 dB suppression of the compound action potential threshold versus saline.

    In plain wordsIn guinea pigs given cisplatin, MT-II did not delay hearing loss compared with saline.

    Peptide
    Melanotan II
    Outcome
    No significant changeDays to reach 40 dB CAP threshold suppression
    Study

    guinea pign: not reported in source

    Albino guinea pigs with cisplatin ototoxicity
    Comparator
    Saline
    Outcome group
    Neuroprotection · Nervous system and cognition
    Studied dose
    3 or 30 microg/kg/day · subcutaneous · 5-18 daysAs given in this study (guinea pig).

    Source sentences

    Summary
    The number of days in which the -40 dB criterion was reached in the MT-II co-treated group did not differ from the period in the saline group.
    1 context sentence
    Summary · context
    Guinea pigs, equipped with a permanent round-window electrode for electrocochleography, were treated with cisplatin (1.5 mg/kg/day intraperitoneal) and simultaneously with MT-II (30 or 3 microg/kg/day subcutaneous) or saline until a 40 dB suppression of the compound action potential (CAP) threshold…
  2. 02AnimalAnimal study (in vivo)Efficacy outcome

    In guinea pigs given cisplatin, recovery of the compound action potential did not differ between MT-II co-treatment and saline.

    In plain wordsIn guinea pigs given cisplatin, hearing recovery with MT-II was no different from recovery with saline.

    Peptide
    Melanotan II
    Outcome
    No significant changeRecovery of compound action potential after cisplatin
    Study

    guinea pign: not reported in source

    Albino guinea pigs with cisplatin ototoxicity
    Comparator
    Saline
    Outcome group
    Neuroprotection · Nervous system and cognition
    Studied dose
    3 or 30 microg/kg/day · subcutaneous · 5-18 daysAs given in this study (guinea pig).

    Source sentences

    Summary
    Ten days after the end of the treatment a spontaneous recovery of the CAP was observed in all groups and at all frequencies, although it was more pronounced at lower frequencies. Also with respect to recovery, no differences were found between the saline and the MT-II co-treated group.
    1 context sentence
    Summary · context
    Guinea pigs, equipped with a permanent round-window electrode for electrocochleography, were treated with cisplatin (1.5 mg/kg/day intraperitoneal) and simultaneously with MT-II (30 or 3 microg/kg/day subcutaneous) or saline until a 40 dB suppression of the compound action potential (CAP) threshold…

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    10 Oct 2026, 09:43 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:04 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.